Based on the pharmacokinetics of the hemophilus influenzae B, purified antigen conjugated vaccine, there are no conceivable porphyrinogenic effects.

Haemophilus influenzae type b polysaccaride conjugated to tetanus carrier protein.

The hemophilus influenza B vaccine is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b in children from 2 months through 5 years of age. It is administered by intramuscular injections, in infants usually according to a three or four dose schedule.

The hemophilus influenza B vaccine is not metabolized by the cytochrome P450 system.